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Resumen
La literatura en epilepsia y el trastorno bipolar en los inductores está contaminada por falsos
negativos. Esta es la primera parte de una revisión exhaustiva de los fármacos antiepilépticas (FAE) con
propiedades inductoras que usa los mecanismos farmacológicos y la medicina basada en la evidencia para
aportar recomendaciones prácticas a neurólogos y psiquiatras sobre el modo de controlar sus efectos. La
carbamazepina, el fenobarbital y la fenitoina son potentes inductores con efectos clínicos relevantes. Se
calculan sus factores de corrección para los fármacos que han sido estudiados. Estos factores de
corrección son una simplificación para orientar a los clínicos, ya que existe entre las personas una gran
variedad en la intensidad de los efectos inductores. A medida que se publique nueva información, deberán
modificarse los factores de corrección. Algunos de estos factores son tan elevados que algunos fármacos
(el bupropion, la quetiapina o la lurasidona) no deberán administrarse conjuntamente con los inductores
potentes. El clobazam, la eslicarbazepina, el felbamato, la lamotrigina, la oxcarbazepina, el rufinamide, el
topiramato, la vigabatrina y el ácido valproico son inductores leves que pueden: a) ser inductores sólo en
dosis elevadas; b) combinar a menudo efectos inhibidores, y c) emplear meses en alcanzar sus efectos
inductores máximos o su desaparición, e indudablemente necesitan más tiempo que los inductores
potentes. Claramente, los inductores potentes, y posiblemente los inductores débiles, tienen efectos
relevantes en el metabolismo endógeno de a) las hormonas sexuales, b) la vitamina D, c) las hormonas
tiroideas, d) el metabolismo lipídico, y e) el ácido fólico.
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Abstract
The literature on inducers in epilepsy and bipolar disorder is seriously contaminated by false
negative findings. This is part I of a comprehensive review on antiepileptic drug (AED) inducers using
both mechanistic pharmacological and evidence-based medicine to provide practical recommendations to
neurologists and psychiatrists concerning how to control for them. Carbamazepine, phenobarbital and
phenytoin, are clinically relevant AED inducers; correction factors were calculated for studied induced
drugs. These correction factors are rough simplifications for orienting clinicians, since there is great
variability in the population regarding inductive effects. As new information is published, the correction
factors may need to be modified. Some of the correction factors are so high that the drugs (e.g.,
bupropion, quetiapine or lurasidone) should not co-prescribed with potent inducers. Clobazam,
eslicarbazepine, felbamate, lamotrigine, oxcarbazepine, rufinamide, topiramate, vigabatrin and valproic
acid are grouped as mild inducers which may (i) be inducers only in high doses; (ii) frequently combine
with inhibitory properties; and (iii) take months to reach maximum effects or de-induction, definitively
longer than the potent inducers. Potent inducers, definitively, and mild inducers, possibly, have relevant
effects in the endogenous metabolism of (i) sexual hormones, (ii) vitamin D, (iii) thyroid hormones, (iv)
lipid metabolism and (v) folic acid.
Key words: anticonvulsants; antidepressants; antipsychotic agents; drug interactions; enzyme, induction;
enzyme, inhibition.
Footnote: Table 1 and 3 were included in second part of this article but they are included here to facilitate
reading.
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Introduction
In a two-part editorial in which Part I1 focuses on epilepsy and Part II2 focuses on bipolar disorder,
the author proposed that the neuropsychopharmacology literature on drug-drug interactions (DDIs) with
drug metabolic inducers is seriously contaminated by false negative findings. Inducers’ effects are
systematically denied or at least undervalued, and the available published literature systematically
deemphasizes their clinical relevance. Moreover, this pattern of denial occurs both in epilepsy1 and
bipolar disorder2 literature, where inducers increase the metabolism of many drugs metabolized by the
Cytochrome P450 (CYP) and/or Uridine Diphosphate Glucuronosyltransferase (UGT) enzymes. This
pattern of denial may be defined as systematic since it contaminates different pharmacological categories:
(1) CYP3A4 drugs, (2) non-metabolized drugs, and (3) mild inducer drugs.1,2 Moreover, it contaminates
the “narrative” of both epilepsy1 and bipolar disorder2 pharmacological treatments which are
characterized by polypharmacy, including the use of potent inducers such as carbamazepine or the more
recently introduced mild inducers, such as oxcarbazepine. Historically, denial has usually occurred first in
the antiepileptic drug (AED) literature1 and then is repeated in the literature on bipolar disorder.2
This review article attempts to provide a comprehensive review of the AED inducer literature to
establish the current status of the field in order to provide practical recommendations to clinicians (Part I).
Part II reviews the pharmacological mechanisms behind induction and provides further information to
interpret AED DDIs in the real world which frequently include other pharmacological mechanisms
besides induction. .
Part I includes sections on (1) the literature search (for Parts I and II); (2) the limitations of using a
practical approach in providing guidelines for clinicians on inducer DDIs; (3) potent inducers, including
subsections on the 3 major potent inducers, carbamazepine, phenobarbital and phenytoin, a brief
subsection on primidone, and these potent inducers’ effects on major drug classes; (4) mild inducers, with
subsections on clobazam, eslicarbazepine, felbamate, lamotrigine, oxcarbazepine, rufinamide, topiramate,
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vigabatrin and valproic acid (VPA); and (5) a description of AED inducer effects, which go beyond DDIs
and include effects on the metabolism of endogenous compounds.
Literature search
The author has been conducting PubMed searches in this area for more than 15 years in the
process of publishing 1) review articles in this area,3-9 2) studies of the effects of AED inducers in
psychiatry,10-19 and 3) a book with practical guidelines for each AED and/or mood stabilizing agent;
the book has more than 1000 different references.20 All of these were published in the context of trying to
develop a comprehensive model of personalized prescription in psychiatry.21-26 In that sense, adding or
discontinuing an inducer is equivalent to decreasing or increasing the dose of the substrate, which is
considered a form of personalized dosing.21 Recommending against using a powerful inducer in the
context of using a substrate (e.g., phenytoin in a patient taking quetiapine) is considered a form of
personalized drug selection.21
The comprehensive searches for individual AEDs with inductive properties conducted in April
2011 were updated for each AED in December 2013 for this article. A PubMed search for
eslicarbazepine pharmacokinetics was also conducted since the author had not completed prior searches
on this compound before writing this article.
Limitations of a practical approach in providing guidelines for clinicians
This review targets clinicians for the purpose of resolving the practical problems regularly
encountered by psychiatrists and neurologists who frequently manage patients taking polypharmacy
regimens. The author works as a consultant in Kentucky’s public mental health system and his daily
experience is that psychiatrists and neurologists are unaware that AED inducers exert a major influence
on the dosing of other drugs; they have limited understanding of how to correct for these effects. This is a
review for practicing clinicians, but it may not completely satisfy readers with a scientific orientation.
Two major groups of scientists work in the field of psychopharmacology: the basic scientists who focus
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on pharmacological mechanisms and those who take a statistical approach, the so-called evidence-based
medicine approach (EBM).27
Mechanistic Approach
Pharmacologists working in a laboratory may argue28 with the practical classification of potent
and mild inducers used in this review article. Smith et al.28 would point out that all AED inducers,
independent of their potency, use the same mechanism for induction; from the pharmacological point of
view, potency may be defined by the affinity of the inducer to the induced enzyme. That is obviously
correct from the pharmacological point of view, but our ability to extrapolate from this understanding of
the pharmacological mechanism behind induction applications for the clinical environment is rather
limited. It is insufficient for producing a simplified classification for clinicians fundamentally interested
in managing their patients. In that sense, the review of our limited understanding of the pharmacological
mechanism behind induction is left for Part II of this article, which can be read by clinicians with further
interest. As many specific DDIs have not been systematically studied and no information is available to
orient clinical decisions, the author must frequently, in his own clinical practice, extrapolate from other
drugs with a similar metabolic profile by following mechanistic pharmacokinetic principles. However, the
author has learned to be extremely careful when extrapolating from other pharmacological DDIs, as the
literature is systematically biased against the inductive effects of AEDs and is frequently contaminated
with incorrect statements that get repeated from one article to the next. The best examples of incorrect
statements on the effects of inducers refer to topiramate among AEDs and paliperidone among drugs used
in bipolar disorder.
Many articles remind us that topiramate is mainly eliminated unchanged in the urine, but in truth it
is partly metabolized (the figure usually quoted is 20%) by CYPs.29 As far as the author knows, the
specific CYPs have never been studied. Unfortunately, the literature does not stress that metabolism under
normal conditions is not the same as metabolism under induction. Although topiramate metabolism under
induction has not been well studied, it is clear that topiramate clearance increases two-fold when taking

29
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carbamazepine or phenytoin, which requires doubling the dose. Therefore, when powerful inducers are
prescribed, a larger proportion of topiramate is metabolized, probably around 40%. The paliperidone
paliperidone prescribing describes a decrease of 37% paliperidone area under the curve (AUC) after
taking 400 mg/day of carbamazepine for unspecified period. That period recently has been recently
described to be 3 weeks30 which is not sufficient to reach maximum carbamazepine induction. For years,
based on his experience with risperidone,10,11,13 the author31 had hypothesized that risperidone’s main
metabolite, marketed as paliperidone which was not supposed to be metabolized according to the
marketer, may be like topiramate, quite susceptible to induction. Recently, Yasui-Furakori et al.32 have
demonstrated that the author’s hypothesis was correct; 600 mg/day of carbamazepine for 2-4 weeks was
associated with an average reduction in plasma paliperidone concentrations to one-third. This will require
multiplying the paliperidone dose by 3 in these patients. It is possible that an even higher paliperidone
correction factor will be needed in patients taking higher carbamazepine doses or for longer periods of
time.
EBM Approach
Scientists with a strict EBM approach will never be satisfied with the recommendations provided
in this review article because many of them are based on case reports or on extrapolations based on what
we know about the pharmacokinetic mechanisms of drugs with similar metabolism. Neglecting the value
of extrapolation can have deleterious consequences. Based in extrapolative thinking that oxcarbazepine
may be a less potent inducer that carbamazepine, the author hypothesized that oxcarbazepine has
inductive effects on lamotrigine and subsequently detected in real life two cases of initial Stevens Johnson
syndrome,12 preventing the progression of a potentially lethal adverse drug reaction (ADR).
EBM approaches are naturally limited in the literature on inducers since, as the author has
described,1,2 the current literature is contaminated by a systematic bias denying the clinical relevance of
AED inducers. It is very easy to design a randomized clinical trial (RCT) using AED inducers which will
produce negative results; one only has to prescribe the inducers using doses or durations below those

7
needed to detect induction; a negative trial will result and one can conclude that inducer A has no effect
on substrate B. 1,2 Unfortunately, few RCTs have been designed by pharmaceutical companies to study DI
with inducers in clinically-relevant conditions in order to provide recommendations for clinicians.
This author could then conduct a discussion of the type errors in statistics, which is relevant for
the EBM approach, but he prefers to acknowledge that we do not live in an ideal world. In an ideal world,
one would like to follow EBM principles by conducting hundreds of RCTs. They would provide
recommendations to clinicians on appropriate co-prescription of AED inducers in situations of
polypharmacy. Conducting hundreds of RCTs would be quite expensive and require massive effort. In the
real world, which includes the absence of extensive funding in this area, the author has been involved in
using already-collected samples to explore inductive effects. The most successful outcome has resulted
from his valproic acid (VPA) studies on clozapine metabolism. In the first study,14 a sophisticated
mathematical model demonstrated that VPA may be an inducer of clozapine metabolism by using a
convenience sample comprised of a total of 415 plasma clozapine samples collected for other purposes.
These samples were obtained for therapeutic drug monitoring (TDM) in 83 patients sent by their
clinicians for clinical purposes and for previously published DI studies in 172 patients.14 Unfortunately,
the same type of mathematical model was unable to demonstrate VPA inductive effects on olanzapine in a
sample of convenience including a total of 360 plasma olanzapine samples.15 The samples were obtained
by combining TDM from 116 patients and DI studies from 47 patients.15 The lack of induction of VPA on
olanzapine metabolism was somewhat surprising since olanzapine and clozapine metabolism are rather
similar. To detect VPA inductive effects, a more sophisticated design was required; a much smaller
olanzapine study (18 patients, 3 samples per patient, a total of 46 olanzapine samples) with a prospective
design demonstrated VPA inductive effects on olanzapine metabolism.16 Unfortunately, this prospective
study raised more questions as well by indicating that VPA may also competitively inhibit olanzapine
metabolism and that VPA duration may be important in determining the net effects (induction versus
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inhibition). As a matter of fact, it is possible that four weeks of VPA treatment in this prospective study
17

was not long enough to reach maximal induction of olanzapine metabolism.
Although the prior paragraph stresses the need of higher levels of evidence in DDI, a completely
developed EBM approach may not resolve these questions for all patients. Well-controlled studies tend to
focus on average patients but, in the clinical world, many patients, called outliers by statisticians, do not
follow average patterns and are not well represented by the means. The author has no knowledge of
patients who are completely resistant to inducers and who show no clinically relevant induction of potent
inducers using doses and durations expected to cause it, but he would not be surprised if they exist. He
has extensive experience with the relatively rare patients (probably <1%) who appear to have very
powerful responses to inducers. A few of them are briefly described in Table 1, since the literature rarely
acknowledges their existence.
Combining Mechanistic and EBM Approaches
In reviewing the literature, the author has tried to combine the mechanistic pharmacological and
EBM approaches in an attempt to obtain the best recommendations for clinicians at this time. The
reinterpretation of vigabatrin and clobazam potential for DDIs may be the best examples of this combined
thinking by the author. Both drugs were used in Europe for many years and were not considered inducers.
Their introduction in the USA mandated Food and Drug Administration (FDA) requirements such as in
vitro studies of their potential for DDIs, which demonstrated that both drugs are mild inducers. This has
led the author1 to review the old RCT that, in effect, suggested that these drugs were mild inducers, but
the old articles ignored or even rejected the possibility that these two drugs were inducers. Vigabatrin and
clobazam teach the lesson that the literature in this area is quite unreliable. Based on the limitations of old
literature, one can easily prognosticate that in 5 years this review article may be obsolete and need
extensive modifications, including dosing modifications.
Potent inducers

33,34

There is general agreement in the literature
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that three AEDs, carbamazepine, phenobarbital and

phenytoin, are clinically relevant inducers. In reality, all barbiturates are believed to be inducers, although
this review only briefly mentions another one of them, primidone. Table 233-36 provides a summary for
clinicians of the common characteristics of these potent inducers. Clinicians interested in better
understanding the various CYPs and UGTs and the relevance of their induction are encouraged to look at
Table 3. Some information indicates that it is possible that phenytoin may be a more promiscuous and
potent inducer than carbamazepine, since it has been reported that adding phenytoin may require doubling
the dosage of carbamazepine,37 which indicates that phenytoin pushes the induction beyond
carbamazepine’s own self-induction. As phenobarbital is currently much less frequently used in
developed countries, there is very limited information on its inductive properties in clinical samples.
Table 4 provides correction factors calculated by the author using the available literature.6,14,32,38-57
Adding a potent inducer requires increasing the dose of the substrate. For example, a correction factor of
2.0 indicates that the substrate dose should be doubled. If the patient is taking an inducer and a substrate,
and the inducer is discontinued to maintain the same plasma concentration of the substrate, one should use
the inverse of the correction factor 1/2.0=0.5, or halve the dose. Table 4 provides recommendations based
on the limited information available; as more articles are published; these correction factors will need to
be recalculated. References are provided in case the reader wants to update them. Remember that
correction factors are average corrections for average patients; thus, an individual may have a metabolic
capacity higher or lower than average. Sometimes TDM can be used to make more precise corrections in
an specific individual.6,25
Carbamazepine
Carbamazepine is a classic AED that is approved in the US for partial onset epilepsy, bipolar
disorder and trigeminal neuralgia.20 Carbamazepine is mainly metabolized by CYP3A (with a minor
contribution from CYP2C8) to its active metabolite, 10,11-epoxide, which may account for 40% of
carbamazepine metabolism, but the proportion is even greater in patients with induced CYP3A4 activity.
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The epoxide is subsequently transformed into the inactive diol by an epoxide hydroxylase. Other
pathways include aromatic hydroxylation (25%), possibly by CYP1A2, and glucuronidation of the
carbamoyl side chain by UGTs, presumably primarily by UGT2B7.20
Carbamazepine induces its own metabolism (Table 2), increasing it by three times.20 When
starting carbamazepine, levels may not be in steady state for the first 3-5 weeks due to the progressive
increase in auto-induction. Table 4 provides correction factors for several drugs during carbamazepine
treatment.
Phenobarbital
Phenobarbital is a classic AED that is approved in the US for generalized and partial onset
epilepsy and for sedation.20 Phenobarbital is eliminated unchanged in urine (20-50%) and metabolized to
parahydroxyphenobarbital and phenobarbital N-glucoside. CYP2C9 plays a major role in the formation of
parahydroxyphenobarbital. Other minor metabolizing enzymes are CYP2C19 and CYP2E1.20
The literature does not indicate that phenobarbital causes auto-induction (Table 2). Knowing its
inductive profile of being a CYP2C9 inducer, it is possible that self-induction occurs but it is probably
modest and not easy to detect due to phenobarbital’s extraordinarily long half-life (several days). Table 4
provides correction factors only for clozapine and paroxetine since there is no information for other drugs.
If there is need, the recommendation is to use correction factors for carbamazepine and/or phenytoin as
rough approximations.
The literature suggests that phenobarbital’s AED inductive effects are mild (and probably not
clinically relevant, < 1/3 decrease in levels) for several AEDs including felbamate; lacosamide,
levetiracetam, pregabalin and rufinamide.20
Phenytoin
Phenytoin is a classic AED that is approved in the US for generalized and partial onset epilepsy
and prevention of seizures secondary to surgery or head trauma.20 Phenytoin is extensively parahydroxylated by CYP2C9 while CYP2C19 may be the second most important enzyme for this step. Other

20
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less important enzymes may be CYP2C8 and CYP3A. Phenytoin is a mild inducer of its own
metabolism, according to a study in volunteers58 which is compatible with in vitro studies showing only
mild to moderate inductive effects on the CYP2C subfamily.35 More importantly than auto-induction,
clinicians need to be very aware that phenytoin can inhibit its metabolism by saturating CYP2C9 and
CYP2C19. Phenytoin can be described pharmacologically as having a narrow therapeutic window and
following nonlinear pharmacokinetics; its kinetics are dose-dependent and capacity-limited. In the
experience of the author, dosing beyond the recommended upper range of the therapeutic window of > 20
mcg/ml yields the saturation of the enzymes and the increase of half-life, which will require the complete
discontinuation of phenytoin for at least 2-3 days until normal metabolism recovers to levels < 20 mcg/ml
and closely-followed TDM. In situations of high plasma phenytoin concentration (close to 20 mcg/ml),
adding any CYP2C inhibitor or any drug that competes with CYP2C9 and/or CYP219 may be
accompanied by dramatic concentration increases that probably would not occur if phenytoin
concentrations were considerably lower (e.g., 10 mcg/ml). Table 4 provides correction factors for several
drugs during phenytoin treatment.
Primidone
Primidone is a classic AED that is approved in the US for generalized and partial onset epilepsy. It
is rarely used in epileptic patients resistant to other treatments and those with essential tremors.20 Up to
one quarter of primidone is eliminated unchanged in urine and the remainder is metabolized by the
CYP2C isoenzymes to two active metabolites: phenobarbital and phenylethylmalonamide. As primidone
is transformed into phenobarbital, one should consider it as powerful an inducer as phenobarbital.20 Table
4 does not provides correction factors for primidone; if there is need, the author would suggest using
phenytoin’s correction factors as an approximation.
Effect of potent inducers on major drug classes
This subsection comments on AEDs, psychiatric and medical drugs. AEDs are too heterogeneous
in their metabolism to be briefly reviewed as a group, but Table 4 provides data on correction factors for
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several of them when potent inducing AEDs are administered. Three psychiatric drug classes
(antipsychotics, antidepressants and benzodiazepines) and non-neuropsychopharmacological drugs
metabolized by CYP3A4 are reviewed briefly in this section.
When clinicians want to consider adding a potent inducer in a patient taking an antipsychotic, they
should consider the risk of induction and review the most current literature. A recent review of secondgeneration antipsychotics6 indicated that antipsychotics can be divided into three groups: those needing
massive dose increases, those needing minimal or no increases, and those in an intermediate group
needing moderate to significant dose increases. Lurasidone and quetiapine need massive increases in
dosing (see Table 4). In that 2012 review article, amisulpride, paliperidone and ziprasidone were
classified as needing minimal or no increases but as previously indicated, the recent study from YasuiFurakori et al.32 demonstrated that paliperidone should be eliminated from this group of antipsychotics
needing minimal or no increases after adding potent AED inducers and include in the group requiring
moderated increased. Thus, the intermediate second-generation antipsychotics are those dependent for
their metabolism on CYP1A2 and UGTs (clozapine and olanzapine), those partly dependent on CYP3A4
(aripiprazole, iloperidone and risperidone), and probably paliperidone (see Table 4). Currently, the author
has no information to indicate whether potent inducers influence asenapine metabolism or not.6 There is
very limited information on correction factors for first-generation antipsychotics (see Table 4 for
haloperidol).
The information of the effects of potent inducers on tricyclic antidepressants (TCAs) is limited.
Tertiary amines such as amitriptyline, clomipramine and imipramine are demethylated by CYY2C19 and,
to a lesser extent, CYP1A2, CYP2C9 and CYP3A4; all of these CYPs can be induced.10 Secondary
amines such as nortriptyline and desimipramine are hydroxylated by CYP2D6 and possibly other CYPs.10
Thus, if a patient is taking a TCA and potent inducers of TCAs, TDM should be used. Table 4 provides an
approximate correction factor of 2.0, but the range, based on review,41 is 1.4-2.5. This indicates that it is
better to use TCA TDM when trying to correct for the effect of a potent inducer in a patient taking a TCA.
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There is very limited information on the effects of potent inducers on the metabolism of secondgeneration antidepressants.8,38,53,59 Table 4 provides correction factors for citalopram, milnacipran,
mirtazapine, sertraline and paroxetine in patients taking carbamazepine; for paroxetine in patients taking
phenobarbital; and for citalopram and paroxetine in patients taking phenytoin. Bupropion is included as
Footnote a in Table 4 because 10.0 is the correction factor calculated by the author from the limited
information available.8 Bupropion is mainly metabolized by CYP2B6, which is very sensitive to
induction; therefore, bupropion should be avoided in any patient taking potent inducers since the
pharmacy may not want to dispense bupropion in doses 10 times higher than usual. Reboxetine and
vilazodone, which are mainly metabolized by CYP3A4, may be particularly sensitive to induction.
According to data from antipsychotics dependent on CYP3A4, they may require a correction factor of at
least 5.8
Benzodiazepines are heterogeneous in their metabolism but three major groups exist: those
metabolized by (1) CYP3A4, (2) CYP2C19 and CYP3A4, and (3) UGTs. CYP3A4 accounts for 93%60 of
triazolam’s metabolism, 92%60 of midazolam’s, and 75%60 of alprazolam’s. These three benzodiazepines
are likely to be strongly induced by potent inducers and they should be avoided in patients taking potent
inducers. Clonazepam is partly metabolized by CYP3A4; Table 4 provides correction factors for
carbamazepine and phenytoin. Lorazepam and oxazepam are not metabolized by CYPs but by UGTs.61
No studies exist, but potent inducers are likely to have clinically relevant effects on lorazepam and
oxazepam. Similarly, there are no good studies of the effects of potent inducers on diazepam and
clobazam, which are metabolized by CYP3A4 and CYP2C19. The limited clobazam data62,63 indicates
that, although carbamazepine is likely to be an inducer, phenytoin may induce CYP3A4 but also compete
with CYP2C19 metabolism.6
All three potent AED inducers are potent CYP3A4 inducers. Many nonneuropsychopharmacological drugs are extensively metabolized by CYP3A4, including many calcium
channel blockers, statins, immunosuppressants and estrogen-containing oral contraceptives. Clinicians

14
combining carbamazepine, phenytoin, or phenobarbital with any drug from any of these drug classes must
pay attention to the lack of efficacy associated with decreased plasma concentrations and consider
increasing doses of these substrates or switching to similar drugs not metabolized by CYP3A4. If the
drugs are mainly metabolized by CYP3A4, the correction factor will be ≥ 5. This is based on the
correction factor of quetiapine (Table 4), which has been estimated to be 85% metabolized by CYP3A4.64
The case of antiretroviral agents is particularly complex. All three potent AED inducers should be avoided
in patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors.65
Mild inducers
This article groups clobazam, eslicarbazepine, felbamate, lamotrigine, oxcarbazepine, rufinamide,
topiramate, vigabatrin and VPA as mild inducers. As far as the author knows, no other author has grouped
them together in the same way, nor has contrasted them to the powerful inducers (Table 5). Thus, a
summary of their inductive enzymes includes their inhibitory properties (Table 6) to help the reader
understand that these AEDs have a very complex DDI profile.
Clobazam
In the 1970s clobazam was first approved in Australia and then in France for anxiety and epilepsy.
In 2011 it was approved in the US for the adjunctive treatment of seizures associated with LennoxGastaut syndrome.9 Clobazam’s major metabolic pathway involves N-demethylation, primarily by
CYP3A4, and to a lesser extent by CYP2C19 and CYP2B6. N-desmethylclobazam is an active metabolite
extensively metabolized, mainly by CYP2C19. N-desmethylclobazam and its metabolites comprise
approximately 94% of the total drug-related components in urine.9
In vitro studies indicate62,63 that (1) N-desmethylclobazam is a weak inhibitor of CYP2D6,
CYP2C9, UGT1A4, UGT1A6 and UGT2B4; and (2) clobazam and N-desmethylclobazam induced
CYP3A4 activity in a concentration-dependent manner. It is surprising that clobazam is a mild CYP3A4
inducer because clobazam is a benzodiazepine, and benzodiazepines are not thought to be inducers.
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Therefore, clobazam auto-induces its own metabolism (since it is metabolized by CYP3A4 and is
an inducer of CYP3A4); however, by carefully reviewing an old study,66 this author1 has concluded that
auto-induction may not start until the third week of treatment. As in vitro studies indicate, the inductive
effects depend on both clobazam and N-desmethylclobazam and are concentration-dependent. It is
important to know that N-desmethylclobazam requires several weeks to reach steady state,9 and it is likely
that clobazam maximal induction may take months until the effects of steady state N-desmethylclobazam
are completely developed.
Clobazam is definitively a midazolam inducer63 which is not surprising since midazolam is mainly
(92%)60 metabolized by CYP3A4. The US prescribing information offers conflicting interpretations of
clobazam induction’s clinical relevance, since it states that dosage adjustment of drugs that are primarily
metabolized by CYP3A4 is not needed but then states that adding clobazam may be associated with the
loss of oral contraceptive efficacy,62 which could only be explained by CYP3A4 induction.
The literature provides conflicting information on clobazam’s inductive effects of carbamazepine,
which is mainly metabolized by CYP3A4, but at the same time induces its own metabolism and can be
partly inhibited by N-desmethylclobazam.1 Similarly, the clobazam information on the possibility of UGT
induction is conflicting.1 Clobazam’s US prescribing information62 reported that population
pharmacokinetic studies during the clobazam RTCs indicated no effects on the metabolism of valproate
and lamotrigine while some,67 but not all, TDM studies1 indicate that clobazam may be a mild inducer of
lamotrigine metabolism. A TDM study indicated that clobazam may mildly reduce serum levetiracetam
concentrations.68
Eslicarbazepine
Eslicarbazepine acetate is a second-generation AED launched onto the European market in 2009
for adjunctive treatment in adult subjects of partial-onset epilepsy,69 but not yet available in the US. After
absorption, eslicarbazepine acetate is rapidly and extensively (95%) hydrolyzed in the first-pass
metabolism at the liver and gut to eslicarbazepine (also known as S-licarbazepine or S-MHD). Another
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5% is oxidized to oxcarbazepine and R-licarbazepine (or R-MHD). Metabolites eliminated in the urine
include 2/3 of the total dose as S-MHD and 1/3 as glucuronide conjugates probably mediated by
UGT1A1.70 Eslicarbazepine acetate is mainly a pro-drug of S-MHD.69
Eslicarbazepine does not self-induce its own metabolism, but appears to be a clinically relevant
inducer of CYP3A4, demonstrated by increasing the clearance of simvastatin by approximately 271 and of
the ethinyl estradiol and levonorgestrel present in oral contraceptives in a dose-dependent manner.72
Eslicarbazepine may also be a weak UGT inducer, slightly increasing (<20%) the clearance of several
AEDs including carbamazepine, lamotrigine and topiramate.48 In vitro studies indicate that
eslicarbazepine is a moderate CYP2C9 and CYP2C19 inhibitor, which is compatible with increasing
phenytoin levels by one-third.48
Felbamate
Felbamate is a second-generation AED approved in the US for epilepsy that responds inadequately
to alternative treatments and is so severe that a substantial risk of aplastic anemia and/or liver failure is
deemed acceptable.20 Approximately 40-60% of felbamate is excreted by the kidneys and is metabolized
by hydroxylation (by CYP3A and CYP2E1) and glucuronidation. CYP3A contributes in a greater extent
to its metabolism when inducers are prescribed. Felbamate is an inhibitor of CYP2C19 and ß-oxidation
and an inducer of CYP3A.20 There is very limited information on the relevance of felbamate’s inductive
effects.
Lamotrigine
Lamotrigine is a second-generation AED approved in the US for several types of epilepsy and for
maintenance treatment of bipolar disorder.20 Glucuronidation is the major metabolic pathway, accounting
for up to 65-90% of lamotrigine metabolism.61 The main metabolite is the inactive 2-N-glucuronide.
Lamotrigine and its metabolites are eliminated in the urine. Reviews suggest that UGT1A4 may
metabolize lamotrigine. There is disagreement on the importance of UGT27B as a metabolic enzyme for
lamotrigine.20
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Lamotrigine is a weak inducer of glucuronidation and of its own metabolism (<20% reduction
within 2 weeks). The effect of this auto-induction is not seen in patients already taking more potent
inducers.20
Lamotrigine may be associated with small (<25%) reductions in VPA levels.73 There are relatively
few well-controlled studies on the effects of lamotrigine on antipsychotic levels.5,6 A mild decrease of
quetiapine metabolism was described in a quetiapine TDM study,74 but a more recent TDM study
described a decrease of approximately half, which will require doubling the quetiapine dose.75 The best
clozapine studies do not show major effects on clozapine levels.5,6 The olanzapine data is more
complicated and includes an in vitro study suggesting that high lamotrigine concentrations can inhibit
olanzapine metabolism;77 clinical studies failed to demonstrate lamotrigine inhibitory effects.5,6 The lack
of consideration given to smoking status may explain this; lamotrigine might behave as a mild inhibitor of
olanzapine metabolism only in smokers.15 Lamotrigine is not expected to influence second-generation
antidepressants.8.38
Oxcarbazepine
Oxcarbazepine is a second-generation AED that is approved in the US for partial-onset epilepsy.20
Some clinicians, based on its similarity with carbamazepine’s chemical structure and fewer ADRs, use
oxcarbazepine for bipolar disorder and trigeminal neuralgia.
Oxcarbazepine is rapidly reduced by a cytosol arylketone reductase to MHD, also called
licarbazepine, which is the clinically relevant metabolite.20 Therefore, oxcarbazepine acetate is a pro-drug
of both enantiomers S-MHD (80%) and R-MHD (20%).69 MHD is cleared by glucuronidation and, less
so, by oxidation to an inactive metabolite. Renal excretion is the major route for oxcarbazepine excretion
(80% of dose) including glucuronides of MHD (40%); unchanged MHD (27%); conjugates of MHD or
oxcarbazepine (13%); and, in small proportion, the inactive 10,11-dihydroxymetabolite.20
Oxcarbazepine is not an inducer of its own metabolism, as carbamazepine is.77 Oxcarbazepine is a
weak inducer of CYP3A and glucuronidation enzymes and a weak CYP2C19 inhibitor.
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The literature generally agrees that its inductive effects are less pronounced than those of
carbamazepine.78 There is more disagreement on whether oxcarbazepine’s inductive effects are mild and
can be ignored, or are clinically relevant. Unfortunately, the literature has not paid attention to Patsalos et
al.,79 who proposed that only oxcarbazepine doses ≥1,500 mg/day may have inductive effects because this
may explain the conflicting findings. Oxcarbazepine frequently shows no inductive effects in the low to
moderate doses used in controlled studies, but appears to be a mild but clinically relevant inducer in
naturalistic studies. In the best published pharmacokinetic study, Andreasen et al.80 compared 17 days of
1200 mg/day of oxcarbazepine and 800 mg/day of carbamazepine in healthy volunteers; clearance of a
CYP3A-dependent quinidine metabolite respectively increased around 90% and 180%. If one assumes
that this study accurately reflects what happens to CYP3A4 drugs, doses of these drugs would need to be
almost doubled when oxcarbazepine is added versus almost tripling them when carbamazepine is added.
A controlled study using 900-1200 mg/day for 5 weeks showed no relevant effects on risperidone
or olanzapine metabolism.81 Clinicians should be alert that oxcarbazepine, particularly in high doses, may
increase the metabolism of some psychiatric drugs. In fact, a case has been published of a clinically
relevant decrease in clomipramine levels after adding oxcarbazepine.82
A controlled study in healthy subjects performed by a pharmaceutical company suggested that
oxcarbazepine doses of 1200 mg/day do not influence lamotrigine metabolism in patients taking 200
mg/day.83 A TDM study using long-term treatment suggested that serum lamotrigine levels may be mildly
reduced when oxcarbazepine is co-administered, and lamotrigine doses may need to be increased by
approximately 20-30%.47,84 The clinical relevance of this DDI is demonstrated by two cases of
lamotrigine-induced oral ulcers (initial signs of Stevens-Johnson syndrome) two months after
oxcarbazepine discontinuation.12 Oxcarbazepine reduces levetiracetam and topiramate levels by
< 30%.78,85 Oxcarbazepine may also be a minor (21% decrease) inducer of carboxylesterases that
metabolize rufinamide.86
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In summary, high doses of oxcarbazepine can induce CYP3A4, UGT1A4 and possibly other
metabolic enzymes. Controlled studies using ≥1,200 mg/day of oxcarbazepine are needed to establish the
magnitude of its inductive effects in the average patient and the correction factor needed to compensate.
Naturalistic studies and case reports need to consider the possibility that some individuals may be
particularly sensitive to oxcarbazepine inductive effects and demonstrate induction in lower doses.
Oxcarbazepine de-induction may take up to 2 months to completely manifest.
Rufinamide
Rufinamide is a second-generation AED that is approved in the US only for use in LennoxGastaut syndrome.20 Rufinamide is extensively metabolized (only 2-4% is excreted unchanged in urine
and feces). It is not metabolized by CYPs but by carboxylesterases. There are no known active
metabolites.20 Rufinamide is a weak inhibitor of CYP2E1, a weak inducer of CYP3A, and possibly a
weak inducer of some glucuronidation enzymes.20
The effects of rufinamide on other antiepileptic levels may not be clinically relevant. Small
decreases (<15%) appear to occur with carbamazepine and lamotrigine levels.87 Currently, another
rufinamide DDI that is considered relevant is that rufinamide is an inducer of oral contraceptives.
Rufinamide may have no effects on topiramate and VPA levels.87
Plasma levels of psychiatric drugs metabolized by CYP3A may be mildly reduced when coadministered with rufinamide, due to the induction of CYP3A, but this interaction has not been
systematically studied except for triazolam, a CYP3A4 substrate (which may account for 93%60 of
triazolam’s metabolism). Rufinamide increased triazolam metabolism probably by one-third but this was
estimated with a single-dose of triazolam.87 It is difficult to extrapolate to repeated dosing of CYP3A4
substrates in clinical practice, which may be much more influenced by rufinamide.
Topiramate
Topiramate is a second-generation AED that is approved in the US for several types of epilepsy
and migraine prophylaxis20 and in combination with phentermine for weight loss.
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Topiramate is mainly eliminated unchanged in the urine but is partly metabolized by CYP
(approximately 20%). The relative importance of CYP metabolism increases when taking a powerful
inducer, such as phenytoin or carbamazepine, which doubles topiramate clearance due to an increase in
CYP metabolism.29
Topiramate also appears to be a weak inducer of several metabolic enzymes, but induction may be
influenced by topiramate doses. After an in vitro study, Nallani et al.88 proposed that in doses ≥400
mg/day topiramate inductive properties may have clinical significance for CYP3A substrates. In a cohort
of 12 women with epilepsy receiving stable dosages of VPA along with a combination norethindrone, 1
mg/ethinyl estradiol, 35-μg tablet, topiramate doses of 200 mg/day, 400 mg/day, or 800 mg/day caused a
statistically significant dose-related decrease in the mean ethinyl estradiol AUC by 18–30% at the 200- to
800-mg/day dose level.89 The pharmacokinetics of norethindrone remained unchanged. In contrast,
another study found that topiramate doses of 50–200 mg/day did not significantly affect the clearance of
either ethinyl estradiol or norethindrone.90
Topiramate may have complex effects on VPA since it may serve as an inducer by increasing βoxidation but can also inhibit VPA glucuronidation. At low VPA doses β-oxidation is the most important
VPA metabolic pathway and topiramate may behave as an inducer of VPA metabolism.91 At high VPA
doses, glucuronidation is the most important VPA metabolic pathway and topiramate may behave as an
inhibitor of VPA metabolism.92
A small controlled study completed by the company with progressive increases in dosages of up to
400 mg/day for 2 weeks showed no relevant DDI between lamotrigine and topiramate.93 In a controlled
study by independent investigators, topiramate was added to lamotrigine treatment monthly from 100
mg/day to up to 800 mg/day if tolerated; the study demonstrated that in 4 of 7 patients there was a
decrease in lamotrigine metabolism by 40-50%.94 Reimers et al.,95 in a large lamotrigine TDM study
controlled for confounding factors, suggested that topiramate may decrease lamotrigine levels, but the
topiramate doses were not described.
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In summary, high doses of topiramate can induce CYP3A4 and some other enzymes (Table 6).
Controlled topiramate studies using ≥400 mg/day are needed to establish the magnitude of its inductive
effects in the average patient and the correction factor needed to compensate. Naturalistic studies and
case reports need to consider the possibility that some individuals may be particularly sensitive to
topiramate inductive effects and demonstrate them in lower doses. A complicating factor is that in some
situations topiramate may have drug metabolism inhibitory properties.
Vigabatrin
Vigabatrin was first licensed as an antiepileptic agent in the UK and the Republic of Ireland in
1989. By the late 1990s, it had been accepted into mainstream clinical practice in the care of adult and
pediatric patients but reports of severe, persistent visual field defects were associated with vigabatrin.
Twenty years later, vigabatrin was introduced in the US market for patients with refractory complex
partial seizures who have inadequately responded to several alternative treatments and for whom the
potential benefits outweigh the risk of vision loss.
According to the US prescribing information,96 vigabatrin is not significantly metabolized and it is
eliminated primarily through renal excretion. In a study of isotopes using a single-vigabatrin dose to
explore drug clearance, Durham et al.97 found that about 95% of total radioactivity was recovered in the
urine, with the parent drug representing most of it (82%); a metabolite accounted for 3-5% of
radioactivity and another for 1-2%. There are no studies on whether repeated dosing increases
vigabatrin’s metabolized fraction or not. Even assuming that <10% of vigabatrin is metabolized, there is
no doubt that the fraction of vigabatrin that is metabolized increases remarkably in patients taking
inducers, although the increase has not been sufficiently well quantified in the literature.1 Vigabatrin has
very rarely been prescribed as monotherapy and most patients studied in the literature were taking several
other AEDs; most frequently they were taking powerful inducers such as carbamazepine or phenytoin.
Therefore, in the typical vigabatrin patient, metabolism may be clinically relevant and include more than
10% of the dose, due to the presence of inducers.
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An in vitro study used to gain approval in the US market demonstrated that vigabatrin is a
CYP2C9 inducer,96 which explains some old findings of reduction of plasma phenytoin concentrations by
25% that were not evident until the 5th or 6th week.98 The US prescribing information97 recommends that,
although phenytoin dose adjustments are not routinely required, dose adjustments of phenytoin should be
considered if clinically indicated. Mild decreases in VPA and phenobarbital levels have also been
described.96
VPA
VPA is a classic AED that is approved in the US for several types of epilepsy, bipolar disorder and
migraine prophylaxis.20 VPA undergoes hepatic metabolism with < 5% eliminated unchanged in the urine.
Major metabolism occurs by UGTs (40%) and β-oxidation as a fatty acid (30%) with minor CYPdependent metabolism (including CYP2C9, CYP2C19 and CYP2A6). At low doses, β-oxidation may be
the most important pathway, while at therapeutic doses glucuronidation may be more important. Many
UGTs appear to be involved in VPA glucuronidation including UGT1A3, UGT1A4, UGT1A6, UGT1A9,
and UGT2B7 and the primarily intestinal UGT1A8 and UGT1A10.20
VPA is usually considered an inhibitor of several enzymes (Table 6) including CYP2C9, epoxide
hydroxylase, several UGTs and the N-glucosidation pathway of phenobarbital.20 Studies in rats appeared
to suggest that VPA auto-induced its own glucuronidation.99 The first suggestion that VPA may autoinduce its own metabolism were from studies focused on other drugs (felbamate100 and lamotrigine101).
Exploring their effects on VPA led their authors to question whether VPA can auto-induce its own
metabolism in humans.
More recently, information on its inductive properties has been accumulating. VPA induces: 1) its
own metabolism by inducing β-oxidation (prospective study);102 2) CYP3A4 and P-gp gene expression (in
vitro study);103 3) possible UGT1A1 in a patient taking irinotecan (which has an active metabolite SN-38
metabolized by UGT1A1);104 4) aripiprazole metabolism to a mild degree (prospective study),105 5)
olanzapine metabolism (case series,106 TDM,107 and a prospective DI study);15 6) clozapine metabolism

108-109

(case series,
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prospective case, and statistical model on TDM-DI studies

14,19
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); and 6) vitamin D

metabolism in an in vitro study.110 The available information on clozapine-olanzapine metabolism
indicates that VPA can be an inducer and/or a competitive inhibitor. Its net effect (predominance of
induction or inhibition) may depend on time, VPA dose and the presence/absence of smoking.
Other effects of AED inducers beyond DDI
In an excellent recent review on the inductive properties of AEDs from the point of view of
epilepsy, Brodie et al.111 provide a historical perspective, recognizing that the problem has been studied
for the last 30 years112 but an awareness of its magnitude for endogenous metabolism has been apparent
only in the last 10 years. The prior sections focused on the metabolism of exogenous compounds (called
xenobiotics), but potent inducers have other long-term health consequences, since their inductive
properties may influence the metabolism of endogenous compounds and homeostasis at several levels
including 1) sexual hormones, 2) vitamin D, 3) thyroid hormones, 4) lipid metabolism and 5) possibly
folic acid. In the author’s experience, probably due to endogenous compensatory mechanisms, these
inductive effects of endogenous compounds are much less likely to be detected and to be clinically
relevant than those occurring in these compounds are administered as exogenous drugs.
It is obvious that CYP3A4 inducers have powerful inductive effects on sexual hormones
administered as medications. Moreover, several mild inducers (clobazam, eslicarbazepine, oxcarbazepine,
topiramate and rufinamide) have been approved with warnings about pregnancy risk in women using oral
contraceptives as the only contraceptive method. The inductive effects are also observed when sexual
hormones are administered for treating hypopituitarism.113 The effect of potent inducers on endogenous
female and male sexual hormones appears more limited, although in rare cases they can be associated
with diminished potency in men and menstrual disorders in women.114
Vitamin D, as with sexual hormones, is a derivative compound of cholesterol; potent inducers
definitively interfere with its metabolism, which is mediated by CYPs, resulting in the potential for
osteoporosis.115 Moreover, more recent data suggest that mild inducers, including oxcarbazepine,
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topiramate and valproic acid, may also cause osteoporosis due to the induction of vitamin D
metabolism.110,116
UGTs are fundamental for thyroid hormone metabolism, but potent inducers can interfere with
thyroid function117 by increasing thyroid hormone metabolism. Occasionally, oxcarbazepine has also been
associated with hypothyroidism.113,117 In the author’s experience, thyroid abnormalities are more likely
when the endogenous feedback is impaired and frequent when thyroid medication is administered
exogenously and the body cannot compensate for the mild thyroid dysfunction caused by AEDs.
Although it is not well understood, potent inducers may interfere with the metabolism of cholesterol and
other complex lipids and have been associated with hyperlipidemia.118
More controversial is the idea that potent inducers may influence folic acid metabolism, which
may contribute to hyperhomocysteinemia, a possible risk factor for atherosclerosis.119,120 Phenytoin is
clearly associated with gingival overgrowth;121 phenytoin and phenobarbital can cause macrocytic
anemia,122 which has been associated with disturbances in folic acid metabolism. The literature usually
reports that phenytoin may be an inhibitor of the folic acid transporter.121,122
In summary, the effect of potent inducers in the endogenous metabolism of: 1) sexual hormones,
2) vitamin D, 3) thyroid hormones, 4) lipid metabolism, and 5) folic acid are established. The possible
milder effects of some mild inducers in some of these endogenous pathways are starting to be described in
the literature.
CONCLUSION
The author has proposed that the neuropsychopharmacology literature on DDI in both epilepsy1
and bipolar disorder2 is currently seriously contaminated by false negative findings. This comprehensive
review of the AED inducer literature provides practical recommendations to clinicians, while Part II
reviews the pharmacological mechanisms behind induction and how future studies can address the current
deficiencies in the literature.
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Part I acknowledges that even a comprehensive literature review cannot eliminate the limitation of
literature biased toward negative findings. In reviewing the literature, the author has tried to combine the
mechanistic pharmacological and EBM approaches to produce the best recommendations for clinicians at
this time. However, he acknowledges that it is likely that in 5 years this review article may be obsolete
and the correction factors provided (Table 4) may need to be extensively modified.
There is general agreement in the literature33,34 that three AEDs, carbamazepine, phenobarbital and
phenytoin, are clinically relevant inducers (Table 2); however, all barbiturates, including primidone,
should be included as such. Table 4 provides correction factors calculated by the author using the
available literature to correct for the inductive effects of carbamazepine, phenobarbital and phenytoin.
The author needs to acknowledge that using correction factors is a rough simplification for orienting
clinicians, since there is great variability in the population regarding inductive effects.123 The author
started using correction factors over a decade ago3 due to the absence of such practical information in
published reviews. Some of the correction factors are so high that other drugs should not co-prescribed
with potent inducers. Among second-generation antipsychotics that should not be prescribed with potent
inducers are lurasidone and quetiapine. Bupropion is the clearest case of a second-generation
antidepressant that should not be co-prescribed with potent inducers. Phenytoin, besides being a potent
inducer for multiple enzymes, can cause clinically relevant CYP2C9 and CYP2C19 inhibitions by
saturation of these enzymes when plasma phenytoin concentrations are >20 mcg/ml.
The author acknowledges that grouping clobazam, eslicarbazepine, felbamate, lamotrigine,
oxcarbazepine, rufinamide, topiramate, vigabatrin and VPA as mild inducers has never occurred in the
literature, but it is justified because they have common elements (Table 5) and, more importantly, may
help prescribers to learn more about this neglected issue. All of them tend to have mild inductive effects,
frequently combined with inhibitory properties (vigabatrin is the exception; Table 6). They appear to take
months for reach maximum effects or de-induction and definitively longer than the potent inducers (Table
5). Five mild inducers, clobazam, eslicarbazepine, felbamate, oxcarbazepine, in high doses (≥1200
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mg/day), and topiramate in high doses (≥400 mg/day), are CYP3A4 inducers and are likely to have
clinically relevant effects on drugs highly dependent on CYP3A4 for their metabolism, including oral
contraceptives, antipsychotics such as lurasidone and quetiapine, and benzodiazepines such as triazolam,
midazolam and alprazolam. VPA’s inductive properties on clozapine and olanzapine metabolism require
more study, but the author has published information which clearly establishes that it can be clinically
relevant in some patients.
Potent inducers, definitively, and mild inducers, possibly, have relevant effects on the endogenous
metabolism of: 1) sexual hormones, 2) vitamin D, 3) thyroid hormones, and 4) lipid metabolism.
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Table 1. List of patients with extreme sensitivity to inductive effects.
Case 1: CAUCASIAN ♂ INPATIENT WITH SCHIZOPHRENIA AND LATE-ONSET EPILEPSYa
A) Extreme sensitivity to CYP3A4 induction
-Carbamazepine: 1500-2000 mg/dayb was needed in the past to reach therapeutic serum
concentrations.
-Quetiapine: On phenytoin and VPA, the quetiapine C/D ratio was 10 times lower than expected.
On VPA, the quetiapine C/D ratio was 2-6 times lower than expected.
c
-Diazepam: On phenytoin, serum concentrations were undetected despite taking 30 mg/day.
On VPA, diazepam clearance after 30 mg IM was ≥3 times higher than expected.
B) Possible VPA auto-induction when taking concentrate, but not present on divalproex sodium
On concentrate, 5250 mg/dayd was needed to reach therapeutic concentrations.
On divalproex sodium, 2000 mg/daye was enough for therapeutic concentrations.
C) Metabolism of clozapine and olanzapine (CYP1A2 drugs) was normal for a male smoker.e
Case 2: AFRICAN-AMERICAN ♂ INPATIENT WITH SCHIZOAFFECTIVE DISORDERf
A) Extreme clozapine induction by VPA (divalproex sodium)
Smoking (20 cigarettes/day): ≥ 650 mg/day was needed for reaching serum concentrations >350ng/ml.g
Smoking and VPA: ~1200 mg/day was needed for reaching serum concentrations >350ng/ml.h
During smoking induction, the patient demonstrated a high metabolic capacity for clozapine.
Addition of VPA induction led to the highest clozapine metabolic capacity the author has seen.
Case 3: CAUCASIAN ♂ INPATIENT WITH SCHIZOAFFECTIVE DISORDERj
A) Extreme sensitivity to CYP3A4 induction
-Carbamazepine: Up to 2800 mg/dayb was needed to reach therapeutic serum concentrations;
this is partly explained by deposits in fat tissue and high volume of distribution.k
-Risperidone: On carbamazepine, approximately 4 times higher than normal metabolic capacity.
On divalproex sodium, risperidone metabolism was normal.
-Paliperidone: On carbamazepine, high capacity to metabolize paliperidone.
B) Extreme olanzapine induction by VPA (divalproex sodium) and omeprazole
-Olanzapine: On divalproex sodium and omeprazole, 1.5 - 2 times higher than normal metabolism.
Case 4: CAUCASIAN ♂ INPATIENT WITH BIPOLAR DISORDERl
A) Possible VPA auto-induction when taking divalproex sodium
___________
Discharged on 4000 mg/daym
Case 5: ♂ INPATIENT WITH FRONTAL AND TEMPORAL LOBE EPILEPSY AND PSYCHOSISn
A) Extreme sensitivity to UGT induction during phenytoin and phenobarbital treatment
-Lamotrigine: 2.6 times higher than the recommended dosage was needed.o
-Lorazepam: Doses > 20 mg/day were tolerated with no sedation.
Case 6: ♂ INPATIENT WITH TUBEROUS SCLEROSIS AND KIDNEY TUMORSp
A) Increased VPA metabolic capacity when taking phenytoin and VPA
-Divalproex sodium: Dose increased >10,000 mg/day to reach therapeutic serum concentrations.q
-Phenytoin: No changes in phenytoin metabolism and no need for changes in dosage.
a
Followed for 5 years (ages 30 to 35).
b
Usual carbamazepine doses to reach therapeutic concentrations: 800-1200 mg/d. Maximum
recommended dose is 1600 mg/day.124
c
Diazepam is metabolized primarily by CYP2C19; CYP3A4 is an auxiliary enzyme. In this patient
CYP3A4 was probably the primary metabolic enzyme for diazepam.
d
The data was published without a pharmacological explanation.125 VPA C/D ratio was 0.013-0.017.
e
The data was published without a pharmacological explanation.125 VPA C/D ratio was 0.036-0.048.
f
Clozapine C/D ratios have been published.126
g
Followed for > 1 year (age 38)

h

127
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Clozapine C/D ratios ranging from 0.54-0.57 were published.
Clozapine C/D ratios ranging from 0.27-0.37 were published.127
j
Followed for > 1 year (age 28).
k
At the time of highest carbamazepine dose, BMI was 40 with weight of 191 kg. The high dose is partly
explained by obesity.128
l
Followed for 3 months (age 68).
m
VPA C/D ratio was 0.024-0.033 in the first month and decreased to 0.017-0.018 in the second month.
n
Followed for 1 year (age 24).
o
Patient needed 1600 mg/day to get therapeutic serum lamotrigine concentrations. The maximum
recommended dose is 600 mg/day.
p
Followed for 4 years (ages 44 to 48 until he died). He initially had angiomyolipomas in both kidneys. In
the second year, a growing right kidney mass led to possible diagnosis of renal carcinoma and
nephrectomy pathology that suggested angiomyolipoma. In the third year, brain metastasis became
evident.
q
In the beginning when the patient had bilateral kidney tumors, he needed around 5000 mg/day of
divalproex sodium to get therapeutic concentrations with VPA C/D ratios of 0.010-0.018. After
nephrectomy and obvious metastatic renal cancer was present, he needed 10,500 mg/day of divalproex
sodium to get therapeutic concentrations with VPA C/D ratios of 0.005-0.009.
i
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Table 2. Characteristics of potent inducers
Metabolic enzymesa
Timeb
c
CYP
UGTs
Onset Maximal De-induction Metabolism Effects in own metabolism
Carbamazepine CYP2B6, CYP3A4 (++++) Several
1wk34 3 wk34 d3wk33,34
CYP3A4
Auto-induction which takes 3-5 wk
CYP1A2, CYP2A6 (++)
CYP2C (+)
Phenytoin
CYP2B6,CYP3A4 (++++) Several
1-2 wk34 1-2 wk34
CYP2C9 & Mild auto-induction
CYP1A2, CYP2A6 (++)
CYP2C19
Competitive inhibition
CYP2C
Phenobarbital CYP2B6,CYP3A4 (++++) UGT1A1
1 wk33 2-3 wk33 2-3 wk33
Kidney
Auto-induction not described
CYP1A2, CYP2A6 (++)
excretion &
CYP2C, CYP2E1 (+)
CYP2C9
++++: massive induction; ++: moderate induction; +: mild induction. wk: weeks.
a
These potent inducers induce other enzymes including epoxide hydrolase.
b
These are approximated times provided by review articles.29,30 Readers may need to be aware that few studies have been conducted to verify
these times.
c
Not all CYPs have the same ability to be induced by potent inducers. More details are provided in Part II, Table 1. It is believed that potent
inducers have massive effects (++++) on CYP2B6 and CYP3A4. On the other hand, potent inducers have only mild to moderate effects on the
CYP2C subfamily which includes CYP2C8, CYP2C9 and CYP2C19.35 Although the literature is not specific on this point, the author believes
that CYP1A2 may be induced intermediately between the potent effects on CYP2B6 and CYP3A4 and mild effects on the CYP2C subfamily
and described as moderate (++). There is limited information on CYP2A6 suggesting potential for moderate induction (++), but clinicians need
to be aware that few drugs are metabolized by CYP2A6; this is the main metabolic pathway for nicotine. There is limited information on
CYP2E1 which may have mild potential for induction, but clinicians need to be aware that few drugs are metabolized by CYP2E1, although it
is a minor metabolic pathway for alcohol and some antiepileptic drugs.
d
The loss of induction may take longer for CYP1A2 substrates than for CYP3A substrates (respective induction half-lives were 105 and 70
hours, or 4.4 days and 2.9 days.36
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Table 3. CYPs involved in drug metabolism
CYP1A2

Substrates in Neuropsychopharmacology
Clozapine, olanzapine
Melatonin
Tacrine

CYP2B6

Bupropion
Ketamine, methadone, ecstasy

CYP2C9

Phenytoin, phenobarbital

Inhibitors
Fluvoxamine
Ciprofloxacin
Estrogens
Infectionb
Clopidogrel
Ticlopidine
Fluoxetine
Valproic acid
Fluvoxamine
Estrogens
Paroxetine
Fluoxetine

Inducers
Level Other (AED/rifampin)
++
Smokinga
Omeprazole
Cruciferous vegetables
++++ Chinese herbsc
Antiretroviralse
Cotrimazolef
Methadoneg
+
St John’s wort

Pregnancy
Inhibition

Inductiond

Inductionh

Diazepam, clobazam
+
St John’s wort
Inhibitioni
Citalopram, some TCAsj
CYP2D6
TCAs, venlafaxine
No
↑activityk
Risperidone, aripiprazole, iloperidonel
Atomoxetine
Activation of codeine-like drugs
CYP3A4
Carbamazepine
Nefazadone
++++ St John’s wort
Inductiond
Quetiapine, lurasidone
Ketoconazole
Corticoids
Midazolam, alprazolam, triazolam
Erythromycin
Cotrimazolef
Buspirone
Grapefruit juice
Antiretroviralse
Reboxetine, vilazadone
++++: massive induction; ++: moderate induction; +: mild induction. AED: antiepileptic drug.
a
Polycyclic aromatic hydrocarbons in smoke have inductive effects. These compounds also found on chargrilled food and coffee from roasted
coffee beans, which can also have inductive effects.129
b
Respiratory infections, other serious infections, such as pyelonephritis or appendicitis or even major inflammations can inhibit CYP1A2
because the cytokines released inhibit CYP1A2.
c
Sodium ferulate was an inducer of bupropion metabolism in a study. It is the sodium salt of ferulic acid, which is widely distributed in herbs
and Chinese formulas such as Ligusticum, Chuanxiong and Chaihu–Sugan–San.130 Another inducer is baicalin, a flavone glucuronide
extracted from the medical plant Radix scutellariae, which is present in fruits, vegetables, and beverages derived from plants (tea, red wine),
and in a wide range of herbal medicines including Huang-Lian-Jie-Du-Tang, hangeshashinto, San-Huang-Xie- Xin-Tang, Da-Chai-Hu-Tang,
and Xiao-Chai-Hu-Tang.131
d
Pregnancy definitively induces CYP2B6 and CYP3A4.132 According to an in vitro study, CYP2B6 and CYP3A4 are induced by both estrogen
and progesterone. Progesterone also induces CYP3A5.
e
Efavirenz133 and ritonvir134 are definitively CYP2B6 inducers. Several antiretroviral agents can induce CYP3A4.135,136
CYP2C19

f
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Cotrimazole may be an inducer of CYP2B6 and CYP3A4.
In vitro studies indicate that methadone may induce its own metabolism and this may be mediated not only by CYP2B6 but also by
CYP3A4.138
h
It is believed that CYP2C9 increases during pregnancy because phenytoin clearance increases. It cannot be ruled out that mechanisms other
than CYP2C9 induction may explain changes in phenytoin clearance during pregnancy. Estradiol increases the activity of CYP2C9 without
affecting expression by unknown mechanisms.139
i
Estrogens are thought to be competitive inhibitors of CYP2C19, but a recent study suggested that they may inhibit CYP2C19 expression.140
j
CYP2C19 is the main enzyme to demethylate amitriptyline, clomipramine and imipramine. Their metabolites then are further metabolized by
hydroxylation, mainly by CYP2D6.
k
It is not well understood why CYP2D6 activity may increase in pregnancy, since it is believed that CYP2D6 cannot be induced. A recent study
suggested that pregnancy may remove a suppressor of CYP2D6 expression.141
l
Aripiprazole, iloperidone and risperidone are mainly metabolized by CYP2D6, but CYP3A4 is also an important pathway, which may be even
more important under treatment with inducers.
g
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Table 4. Correction factors for potent inducers
Correction factora
Drug
Reference number
CARBAMAZEPINE
6
>5.0 (7.5)
Quetiapine
6
5.0
Lurasidone
34
5.0
Sertraline
6
2.0-4.0
Clozapine
6
2.0-4.0
Olanzapine
35,36
3.0 (2.5-6.0)
Haloperidol
28
3.0
Paliperidone
37
2.0
TCAs
6
2.0
Aripiprazole
6
2.0
Iloperidone
34
2.0
Mirtazapine
6
2.0
Risperidone
38
2.0
Theophylline
39,40
2.0
Topiramate
41
1.5
Felbamate
42,43
1.5
Lamotrigine
34
1.4
Citalopram
44
1.33
Eslicarbazepine
45,46
1.33
Clonazepam
47
1.33
Ezogabine (retigabine)
48
1.25
Paroxetine
49
1.25
Milnacipran
PHENOBARBITAL
12
1.5
Clozapine
50
1.25
Paroxetine
PHENYTOIN
6
5.0
Quetiapine
6
Lurasidone
5.0
6
2.0-4.0
Clozapine
6
2.0-4.0
Olanzapine
37
2.0
TCAs
6
2.0
Aripiprazole
33
2.0
Carbamazepine
6
2.0
Iloperidone
42,43
2.0
Lamotrigine
34
2.0
Mirtazapine
6
2.0
Risperidone
39,40
2.0
Topiramate
41
1.5
Felbamate
51
1.33-1.5
Oxcarbazepine
52,53
1.33-1.5
Clonazepam
47
1.33
Ezogabine (retigabine)
44
1.33
Eslicarbazepine
48
1.25
Paroxetine
a
Bupropion’s correction factor for carbamazepine was 10.0, calculated by the author from the limited
information available.49
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Table 5. Mild inducers: comparison to potent inducers
Potent
Mild
INDUCTION EFFECT SIZE
Individual differences
Present in all individualsa
Variable
b
Dose effects
None within therapeutic doses
Probably yesc
Can be obscured by inhibition
Nod
Yes
(except phenytoin’s inhibition of CYP2C)
CHRONOLOGY
Onset
Weeks
Weeks
Maximum
Weeks
Weeks to monthse
De-induction
Weeks
Weeks to monthsf
a
Although it has not been systematically studied, it is generally accepted that potent inducers tend to
maximally induce all patients as long as they are given doses beyond those causing maximal induction.
b
It is also usually believed that a therapeutic dose for epilepsy should cause maximal induction in most
patients. Therefore, further increased doses beyond therapeutic doses may not cause more induction.
Similarly, giving another potent inducer to a person taking usual doses of one potent inducer may not
make a difference.
c
See the text for information on dose effects on oxcarbazepine, topiramate and VPA.
d
AEDs which are classified as potent inducers are strong inducers and not clinically relevant inhibitors.
Therefore, in most circumstances, it is difficult to miss their inductive effects. An exception may be
phenytoin. See the text on phenytoin.
e
See the text on vigabatrin.
f
See the text on oxcarbazepine.
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Table 6. Mild inducers: their inductive and inhibitory properties
Induced enzyme
Inhibited enzyme
a
(or induced drug )
(or inhibited druga)
Clobazamb
CYP3A4
CYP2C19,c CYP2D6c
UGT1A1
UGT1A4,c UGT1A6,c UGT2B4c
Eslicarbazepine

CYP3A4, UGTsd

CYP2C9, CYP2C19

Felbamate

CYP3A4

CYP2C19
ß-oxidation

Lamotrigine

UGTsd

(olanzapine)a

Oxcarbazepine (high doses)e CYP3A4
UGT1A4

CYP2C19

Rufinamide

CYP3A4
UGTsd

CYP2E1

Topiramate (high doses)e

CYP3A4
β-oxidation
UGT1A4

(VPA glucuronidation)a

Vigabatrin

CYP2C9

VPAf

β-oxidation
CYP2C9
a
(aripiprazole)
UGTsd
(clozapine and olanzapine)a Epoxide hydroxylase, N-glucosidation

VPA: valproic acid.
a
For drugs in parentheses, the enzyme behind the induction or inhibition is not definitively established.
b
Clobazam’s effects on CYP2B6 have not been studied.
c
N-desmethylclobazam is the inhibitor.
d
The specific UGTs are not known.
e
Oxcarbazepine and topiramate may be clinically relevant inducers in high doses (≥ 1200 mg/day for
oxcarbazepine and ≥400 mg/day for topiramate). It is possible that their inhibitory properties may also be
more evident in higher doses.
f
VPA induction is probably dose-related. It is probably dependent on the free plasma VPA. VPA follows
non-linear kinetics, making it difficult to estimate the free plasma VPA using VPA doses.

